Mitchell Brigell
Technik-/Wissenschafts-/F&E-Leiter bei OCUPHIRE PHARMA, INC.
Aktive Positionen von Mitchell Brigell
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
OCUPHIRE PHARMA, INC. | Technik-/Wissenschafts-/F&E-Leiter | - | - |
Aerpio Therapeutics, Inc.
Aerpio Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aerpio Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company focused on advancing innovative therapies for vascular diseases. The firm develops small molecules and monoclonal antibodies for the treatment of vascular disease and enhancement of wound healing. Its two lead programs include a tie-2 activator for diabetic macular edema and vascular leak, and a hypoxia-inducible factor 1-a stabilizer for wound healing and the treatment of inflammatory bowel disease. The company was founded by Joseph H. Gardner and Robert Shalwitz in 2011 and is headquartered in Cincinnati, OH. | Technik-/Wissenschafts-/F&E-Leiter | - | - |
Corporate Officer/Principal | - | - |
Karriereverlauf von Mitchell Brigell
Ehemalige bekannte Positionen von Mitchell Brigell
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
AERPIO PHARMACEUTICALS | Technik-/Wissenschafts-/F&E-Leiter | 01.01.2013 | 01.01.2019 |
Novartis Institutes of Biomedical Research
Novartis Institutes of Biomedical Research BiotechnologyHealth Technology Novartis Institutes of Biomedical Research operates a pharmaceutical research organization. The private company is based in Emeryville. | Corporate Officer/Principal | 01.01.2007 | 01.08.2013 |
ISCEV | Corporate Officer/Principal | - | - |
Ausbildung von Mitchell Brigell
Kansas State University | Doctorate Degree |
Statistik
International
Vereinigte Staaten | 6 |
Deutschland | 2 |
Operativ
Chief Tech/Sci/R&D Officer | 3 |
Corporate Officer/Principal | 3 |
Doctorate Degree | 1 |
Sektoral
Health Technology | 5 |
Consumer Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
OCUPHIRE PHARMA, INC. | Health Technology |
Private Unternehmen | 4 |
---|---|
Aerpio Therapeutics, Inc.
Aerpio Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aerpio Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company focused on advancing innovative therapies for vascular diseases. The firm develops small molecules and monoclonal antibodies for the treatment of vascular disease and enhancement of wound healing. Its two lead programs include a tie-2 activator for diabetic macular edema and vascular leak, and a hypoxia-inducible factor 1-a stabilizer for wound healing and the treatment of inflammatory bowel disease. The company was founded by Joseph H. Gardner and Robert Shalwitz in 2011 and is headquartered in Cincinnati, OH. | Health Technology |
Aerpio Pharmaceuticals, Inc.
Aerpio Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aerpio Pharmaceuticals Inc. is a biopharmaceutical company, which engages in the research and development of treatments for ocular diseases. The firm's product candidate is AKB-9778, a small molecule activator of the Tie2 pathway, which completed the Phase 2a clinical trial for the treatment of diabetic retinopathy. It also develops ARP-1536, a humanized monoclonal antibody that is in preclinical development stage for the treatment of diabetic vascular complications; and AKB-4924, a selective stabilizer of hypoxia-inducible factor-1 alpha, which has completed a single ascending dose clinical trial for the treatment of inflammatory bowel disease. The company was founded by Joseph H. Garder on November 16, 2007 and is headquartered in Cincinnati, OH. | Health Technology |
Novartis Institutes of Biomedical Research
Novartis Institutes of Biomedical Research BiotechnologyHealth Technology Novartis Institutes of Biomedical Research operates a pharmaceutical research organization. The private company is based in Emeryville. | Health Technology |
ISCEV |
- Börse
- Insiders
- Mitchell Brigell
- Erfahrung